Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Ocular Drug Delivery: Review of Present Technologies and Steps Forward | Contract Pharma

What are you searching for?

Sign in
White Papers / Tech Papers

Ocular Drug Delivery: Review of Present Technologies and Steps Forward

Market research estimates performed in the last 6 months have shown that the market size for ophthalmic medications is expected to reach more than 25 billion, by the year 2015. The ophthalmology drugs market classification is based on the type of drugs: treatment-based drugs, over-the-counter (OTC) drugs and ocular anesthetics.

Released By Integral BioSystems, LLC

The Market for Ophthalmic Drug Products: Clinical and Business Need-Driven

Market research estimates performed in the last 6 months have shown that the market size for ophthalmic medications is expected to reach more than 25 billion, by the year 2015. The ophthalmology drugs market classification is based on the type of drugs: treatment-based drugs, over-the-counter (OTC) drugs and ocular anesthetics. In the last decade, market need has driven the ophthalmic drug development industry to make extraordinary strides forward both in drug design and in ocular delivery. Following the high profile scientific breakthroughs of nucleic acid-based cell-targeted therapies (RNAi, aptamers), highly specific receptor-targeted small molecule therapies, efficient cell-permeating small molecules and pro-drugs, retro-metabolic small molecules and drugs with better safety profiles have been the introduction of intelligent drug delivery systems that claim to deliver to the targeted tissue for the required duration. Combined with these clinical need-driven innovations are a plethora of technologies that are business-driven, aimed at product extensions for life-cycle management of existing products. Each of these extensions offers improvements and benefits over current technologies, such as offering preservative-free options, “non-settling” formulations, etc. From a regulatory perspective, the number of 505(b)(2) applications claiming differentiated technologies have risen dramatically, with fewer NDA (505(b)(1) applications for novel new chemical entities (NCEs) than there were in previous years. The repurposing of previously approved molecules for other indications into products re-formulated and optimized for ophthalmic delivery has the advantage of leveraging long-term relevant safety data in humans, offering a regulatory advantage with the FDA approval process. If differentiated, IP protection is sought after, to gain maximum product life cycle extension for these products. In lock-step with these products is the generic ophthalmic products industry, offering high quality, pharmaceutically-compliant products at an affordable cost. Thus, the ophthalmic products industry continues to seek a fine balance between innovation to meet both business and clinical needs and a relatively short regulatory timeline.

Download White Papers / Tech Papers Now

Download White Papers / Tech Papers Now

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics